MARKET

BCLI

BCLI

Brainstorm Cell
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.650
-0.050
-1.06%
After Hours: 4.650 0 0.00% 16:00 04/03 EDT
OPEN
4.740
PREV CLOSE
4.700
HIGH
4.820
LOW
4.550
VOLUME
525.81K
TURNOVER
--
52 WEEK HIGH
10.00
52 WEEK LOW
3.430
MARKET CAP
130.41M
P/E (TTM)
-4.3967
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BCLI stock price target is 11.50 with a high estimate of 14.00 and a low estimate of 9.00.

EPS

BCLI News

More
  • BrainStorm Cell +4% premarket on $1.5M grant
  • seekingalpha · 23h ago
  • BrainStorm Awarded $1.5 Million Non-Dilutive Grant for 2020 by the Israel Innovation Authority
  • GlobeNewswire · 1d ago
  • David Setboun Joins BrainStorm as Executive Vice President and Chief Operating Officer
  • GlobeNewswire · 3d ago
  • BrainStorm Appoints Prof. Jacob Frenkel Chairman of the Board of Directors
  • Benzinga · 4d ago

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About BCLI

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.
More

Webull offers kinds of Brainstorm Cell Therapeutics Inc stock information, including NASDAQ:BCLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCLI stock news, and many more online research tools to help you make informed decisions.